HYDRAFIL
Phase 2- Indications
- Chronic low back pain, Degenerative disc disease
Company intelligence / Profile preview
ReGelTec
Baltimore, Maryland, United Statesregeltec.com ↗
- Ownership
- Private
- Employees
- ~12
- Development stage
- Phase 2
01
Overview
Early clinical results suggest that HYDRAFIL can be safely injected into degenerated discs to restore biomechanical function and relieve chronic lower back pain. The hydrogel mimics the natural disc’s properties and preserves spinal motion. Detailed clinical trial data are not publicly available as of June 2025.
- Therapeutic areas
- Rheumatology
- Modalities
- DeviceHydrogel-based drug delivery therapy
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on ReGelTec.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ReGelTec.